Fact-checked by Grok 2 weeks ago

Selenium disulfide

Selenium disulfide, also known as selenium sulfide, is an with the SeS₂ and a molecular weight of 143.1 g/mol. It appears as a bright that is insoluble in but soluble in and acids, with a of 111°C. The compound is toxic by ingestion and inhalation and can irritate the skin and eyes, necessitating careful handling. Primarily utilized as a and keratolytic agent, selenium disulfide is formulated in shampoos, lotions, or foams at concentrations of 1% (over-the-counter) or 2.5% (prescription-strength) to treat conditions such as , seborrheic dermatitis of the , and on the body. It is included on the World Health Organization's List of Essential Medicines. Its mechanism of action involves an antimitotic effect that slows the turnover rate of epidermal cells, a cytostatic reduction in , and inhibition of yeast growth, which contributes to these dermatological issues. Approved for medical use in the United States as early as , it is applied intermittently—typically twice weekly for conditions—to control symptoms like itching, flaking, and redness, with minimal systemic absorption when used as directed. Common side effects include temporary scalp irritation, dryness, or increased , though serious reactions such as severe allergic responses are rare; precautions advise avoiding contact with eyes, open wounds, or acutely inflamed . Beyond , selenium disulfide has limited industrial applications, such as in production, but its primary significance remains in therapeutic formulations like shampoo.

Chemistry

Properties

Selenium disulfide has the SeS₂ and a of 143.09 g/mol. It is not a single pure compound but a of cyclic oligomers, primarily consisting of eight-membered rings of the general form (SeS)n or more precisely Se_xS{8-x}, where x varies, with and atoms alternating in a crown-like configuration similar to elemental sulfur allotropes. Physically, selenium disulfide appears as a bright . It is practically insoluble in water but dissolves in non-polar solvents such as and . The compound has a of approximately 3.06 /cm³ and a melting point around 100–111 °C, at which it decomposes rather than fully melting. Selenium disulfide exhibits notable , being poisonous upon (with an LD50 of 138 mg/kg in rats) and , and it acts as an irritant to the skin, eyes, and mucous membranes. It is chemically reactive with acids, potentially releasing , and with oxidizing agents; it also decomposes upon heating, emitting toxic fumes of and oxides. The compound shows sensitivity to air and light, which can cause gradual discoloration over time.

Synthesis

Selenium disulfide (SeS₂) is primarily synthesized through the reaction of (H₂S) with (H₂SeO₃) or selenite ions (SeO₃²⁻) under acidic conditions. This method involves bubbling H₂S gas into an of , typically adjusted to a of around 4 with , leading to the precipitation of SeS₂ as an orange solid. The balanced chemical equation for this process is: \mathrm{H_2SeO_3 + 2H_2S \rightarrow SeS_2 + 3H_2O} This reaction proceeds at and is widely used in both and settings due to its simplicity and reliance on readily available . Alternative synthesis routes include the reaction of (SeO₂) with (Na₂SO₃) in aqueous acetic acid. In this approach, SeO₂ is dissolved in glacial acetic acid, and is added to generate the reducing sulfide species, resulting in the formation of SeS₂ precipitate. This method is particularly noted in literature for producing pharmaceutical-grade material and offers advantages in controlling particle size through acid concentration. Sustainable synthesis methods leverage natural resources, such as spring waters containing both H₂S and selenite ions. For instance, from sulfide-rich springs like that in Bad Nenndorf, (approximately 2.4 mM H₂S), can be acidified to pH 4 and supplemented with additional selenite to drive the precipitation of SeS₂, yielding around 66% based on the limiting reactant. This eco-friendly approach minimizes synthetic inputs but requires large volumes of to achieve practical quantities, such as 2.3 g from 20 L. Synthesis in aqueous media often faces challenges, including relatively low yields due to side reactions forming elemental or , and the tendency of the product to into nanoparticles or larger globules (1.1–1.2 µm in diameter). Stabilization is necessary to prevent rapid , which can occur within hours, and is typically achieved by immediate and in the dark. Purification involves collecting the orange precipitate via vacuum filtration, washing with to remove unreacted selenite or excess , and drying at low temperatures (e.g., 50°C) to obtain high-purity powder suitable for further applications. This process ensures removal of impurities like residual acids or minerals from natural sources, yielding a , finely divided product.

Pharmacology

Pharmacodynamics

Selenium disulfide demonstrates antifungal activity primarily against species, including (formerly Pityrosporum ovale), by interfering with fungal cellular metabolism and elevating intracellular (ROS) levels, which impairs the oxygen-eliminating systems of the fungi and leads to reduced growth and scalp colonization. This mechanism contributes to its efficacy in controlling Malassezia-driven conditions like and , as the compound targets the yeast's proliferative capacity without requiring systemic effects. In addition to its antifungal properties, selenium disulfide exhibits a cytostatic effect on epidermal and follicular epithelial cells, acting as an antimitotic agent that slows cell turnover in the basal layer and reduces corneocyte production. This inhibition of hyperproliferation helps mitigate excessive scaling and flaking associated with seborrheic dermatitis and by normalizing the rate of epithelial cell shedding. The compound's keratolytic and mild irritant actions further enhance of dead cells, facilitating the physical removal of adherent fungal elements from the surface, while its poor absorption through intact ensures primarily local therapeutic effects without significant systemic exposure. studies confirm its inhibitory potential against Pityrosporum ovale, with reported minimum inhibitory concentrations ranging from 2 to 64 μg/ml, though clinical formulations employ 0.5–2.5% concentrations to achieve effective activity in topical applications.

Pharmacokinetics

Selenium disulfide, when applied topically to the , demonstrates minimal systemic due to its formulation and the barrier function of intact , with less than 1% of the applied dose penetrating transcutaneously. This low rate is consistent across standard or applications, where the compound primarily exerts its effects locally without significant entry into the bloodstream. Studies involving full-body application in patients with have confirmed no detectable increases in blood or urine levels, underscoring the negligible systemic exposure under typical use conditions. Excretion of selenium disulfide and its metabolites is predominantly achieved through the natural shedding of treated cells, resulting in removal via rather than internal pathways. Urinary and fecal elimination are negligible, aligning with the compound's poor systemic and lack of detectable levels in biological fluids after topical use. This route ensures that the majority of the applied dose is eliminated externally, minimizing any potential for accumulation.

Medical uses

Indications

Selenium disulfide, commonly formulated as selenium sulfide in topical preparations, is primarily FDA-approved for the treatment of (also known as pityriasis capitis), seborrheic dermatitis of the scalp, and (pityriasis versicolor), a superficial of the skin. These indications stem from its antifungal properties, which help manage hyperproliferation of epidermal cells and microbial overgrowth associated with these conditions. It is particularly effective in controlling symptoms of scalp fungal infections caused by yeasts, such as scaling, itching, and in and seborrheic . Guidelines from the and the National Eczema Association recommend selenium disulfide shampoos as a first-line therapy for mild to moderate seborrheic due to their efficacy in reducing colonization and symptom severity. Off-label applications include the management of scalp pruritus associated with various dermatoses and psoriasis of the scalp, where it aids in scale removal and symptom relief, though evidence is primarily anecdotal or from small studies. In veterinary , it serves as an adjunct for treating similar conditions in animals, such as seborrhea and dermatitis in dogs, by promoting epidermal turnover and reducing microbial load.

Administration

Selenium disulfide is available in topical formulations such as 1% and 2.5% s, lotions, and creams, commonly used for and applications. For the treatment of and seborrheic on the , the standard dosage involves applying 1–2.5% to the wet , massaging to lather, allowing it to remain for 2–3 minutes, rinsing thoroughly, and repeating the application before a final rinse; this regimen is typically followed twice weekly for two weeks, followed by maintenance use once weekly or less frequently as needed. For on the body, the 2.5% lotion is applied to affected areas, lathered with a small amount of , left on for 10 minutes, then rinsed thoroughly; this is repeated once daily for seven days. Precautions during include avoiding contact with the eyes, flushing immediately with if contact occurs, and using gloves or washing hands thoroughly after application to prevent , particularly for those with sensitive .

Adverse effects

Common effects

Selenium disulfide, commonly used in topical formulations for and seborrheic , is associated with several mild adverse effects that occur frequently but are generally transient and self-limiting. irritation, dryness, and an increase in normal —affect a small proportion of users, with hair loss reported as less common but occasionally noted in clinical use. These effects may be exacerbated by improper application methods, such as leaving the product on the too long. Oily hair or scalp can result from residues of the formulation, leading to unusual oiliness that typically resolves with thorough rinsing. This side effect is among the more common reactions observed during treatment. Mild burning or stinging sensations upon application are frequently reported, though they usually subside quickly after rinsing and do not require discontinuation of use. Discoloration of , particularly affecting gray, bleached, or perm-treated strands due to selenium staining, is a well-documented mild effect that can often be minimized by prompt and thorough washing.

Serious effects

Selenium disulfide can rarely cause and other hypersensitivity reactions, manifesting as severe skin rash, , or swelling that may require medical intervention. Contraindications for selenium disulfide include application to open wounds, blistered or raw skin, and areas of acute , as these conditions increase percutaneous and risk of adverse outcomes. Use in is not recommended (FDA C) due to limited human data and potential for fetal risk from , though animal studies show no direct teratogenicity. Overuse or prolonged application, particularly on damaged , may lead to systemic resembling selenosis, with symptoms including , , and gastrointestinal upset from excessive absorption. Rare reports document severe necessitating immediate discontinuation and supportive . Mild , if it escalates, can sometimes precede these serious reactions.

History

Discovery and development

Selenium disulfide emerged from mid-20th-century explorations in chemistry, where researchers investigated the compound's potential beyond its established industrial roles, such as in pigments and . Although itself had been known since 1817, the of selenium disulfide for therapeutic purposes gained traction in the early 1950s through simple fusion of elemental and , yielding a material suitable for dermatological testing. Initial laboratory observations of its antifungal properties occurred during dermatological research focused on scalp conditions, where selenium disulfide demonstrated inhibition of fungi like Pityrosporum ovale (now ), a key contributor to and seborrheic . These findings built on broader post-World War II advancements in and , shifting attention from selenium's toxicity concerns to its selective antimicrobial potential in topical formulations. Key studies in the late 1940s and early 1950s further identified disulfide's cytostatic activity, which slows epidermal without excessive toxicity, making it promising for treating hyperkeratotic scalp disorders. This led to early patent filings for stable dispersions, such as US Patent 2,694,669 (filed 1953, issued 1954), which described a hydrophilic, acid-stabilized aqueous suspension of disulfide for use in therapeutic shampoos to control and related infections. By 1951, these developments culminated in the compound's introduction for medical use in the United States, marking its transition from industrial derivatives to targeted dermatological applications.

Regulatory milestones

Selenium disulfide, also known as selenium sulfide, received approval from the U.S. (FDA) for medical use on May 17, 1951, initially through the process by Chemicals. This early approval facilitated its incorporation into topical formulations for scalp conditions. In 1991, the FDA issued a final under the Over-the-Counter (OTC) Drug Review, classifying 1% selenium sulfide as and effective (GRASE) for OTC use in shampoos to control , seborrheic dermatitis, and . Higher concentrations, such as 2.5%, were designated for prescription-only use to address more severe cases, reflecting concerns over potential irritation and absorption at elevated levels. The World Health Organization (WHO) has included selenium sulfide in its Model List of Essential Medicines since 1989, recognizing it as a key topical antifungal agent. Specifically, it is listed under Section 13.1 (Antifungal medicines) as a detergent-based suspension at 2% concentration, underscoring its accessibility and importance for treating dermatological infections in resource-limited settings. This inclusion, maintained through the 23rd List in 2023, highlights its cost-effectiveness and broad therapeutic utility without promoting resistance issues common to systemic antifungals. In , selenium disulfide has been regulated under the European Union's Cosmetics Directive—adopted in 1976 and codified as Regulation (EC) No 1223/2009— as a permitted for antidandruff and anti-seborrheic products. It is classified in Annex III with restrictions limiting use to rinse-off hair products at a maximum concentration of 1%, allowing claims for relief of seborrheic dermatitis symptoms when positioned as a rather than a medicinal product. This framework, established in the 1970s, balances efficacy against safety, prohibiting its use in leave-on products due to absorption risks. Pharmacovigilance efforts in the 1980s led to enhanced labeling requirements for selenium disulfide products, particularly regarding hair discoloration. Following case reports of yellow or orange-red hair shaft changes associated with 2.5% formulations, the FDA and manufacturers updated warnings to advise users on avoidance techniques, such as thorough rinsing, especially for light-colored or chemically treated . These updates, integrated into OTC monographs and prescription guidelines by the mid-1980s, emphasized for dermatologic adverse events to support safe long-term use.

Society and culture

Commercial availability

Selenium disulfide is commercially available primarily in topical formulations such as shampoos for treating and seborrheic . Major brand names include , which offers a 1% concentration over-the-counter (OTC) in the and , and SelSun, available as a 2.5% prescription-strength product in the . Generic versions of these shampoos are widely produced and distributed in various countries, including the , , and select international markets. In terms of accessibility, low-strength (1%) selenium disulfide shampoos are sold OTC in the , , and the , where they are regulated under cosmetics directives allowing use in anti-dandruff products up to specified concentrations. Higher concentrations, such as 2.5%, require a prescription in the , while in and parts of the , availability may vary by country due to local restrictions, with some formulations discontinued in nations like the and . The product holds a dominant position in the anti-dandruff segment, driven by demand for effective treatments for conditions. Formulations vary to accommodate user preferences, including scented options with added botanicals like lavender and for a soothing effect, and unscented versions for sensitive scalps. Export of selenium disulfide products is subject to international regulations due to the compound's , including restrictions on concentrations and labeling requirements to mitigate risks of systemic and environmental impact.

Non-medical applications

Additionally, it contributed to the development of pigments, particularly in the creation of vibrant red and hues through the incorporation of into to form cadmium sulfoselenide solid solutions, enabling artists and manufacturers to achieve stable coloration in paints and coatings during the 19th and early 20th centuries. In pigment production, was used to modify the spectral properties of cadmium-based compounds, producing variations from to that were prized for their opacity and in historical artistic practices. These applications leveraged the compound's ability to form mixed chalcogenide structures, enhancing color intensity without compromising durability, though modern environmental regulations have curtailed widespread use of cadmium-containing pigments due to concerns.

Research

Dermatological studies

A 2024 multicenter, double-blind involving 64 adults with moderate to severe seborrheic compared a 1% selenium disulfide (SeS₂) to a 2% over four weeks, demonstrating a 71% reduction in the Scalp Seborrheic Dermatitis Severity (SSSD) score for SeS₂ versus 69% for ketoconazole, with both achieving (p < 0.001). The trial also reported a 75% reduction in Total Symptom Score (TSS), including superior relief in pruritus (67.8% reduction) compared to ketoconazole (47.1%), alongside improvements in and global irritation. enhanced more rapidly with SeS₂, noticeable by day 7 versus day 14 for ketoconazole (p < 0.001). Analyses of multiple randomized controlled trials (RCTs) confirm SeS₂'s efficacy in symptom relief, with comparable outcomes to and , including 76.2% of patients achieving pruritus resolution after eight weeks versus 29.2% at . These reviews highlight SeS₂'s role in rebalancing scalp microbiota, reducing overgrowth through antifungal activity, though specific reduction percentages vary across studies. For instance, adjunctive SeS₂ use after induction further decreases and abundance while promoting Cutibacterium growth. Long-term studies emphasize therapy's importance, with once-weekly SeS₂ post-induction reducing rates to 8.3% at week 6 and 4.2% at week 8, compared to 41.7% and 12.5% with alone (p = 0.008). Without , recurrence can reach up to 42% within six weeks, underscoring SeS₂'s value over in sustaining remission with no significant differences in prevention between the two in phases. Recent trials from 2023 to 2025 demonstrate SeS₂'s tolerability across demographics, including pediatric populations where it supports symptom management with high satisfaction (92%) and ease of use. A 2025 study on (a milder form of seborrheic dermatitis) in 93 subjects with diverse types, including 30% with curly/coily (types VI–VIII, often in African-origin individuals), showed 76.2% total dandruff reduction and 71.7% pruritus relief after four weeks (p < 0.0001), with microbiome rebalancing and no adverse events. These findings affirm SeS₂ shampoo's broad applicability and safety in varied textures and age groups.

Material science applications

Selenium disulfide (SeS₂) has emerged as a promising cathode material in rechargeable batteries due to its high theoretical capacity, moderate redox potential, and improved electrical conductivity compared to elemental sulfur or selenium counterparts. In lithium-sulfur (Li-S) and sodium-sulfur (Na-S) battery systems, SeS₂ addresses limitations such as polysulfide shuttling and low utilization by forming stable composites that enhance cycle life and rate performance. For instance, a pyrolyzed polyacrylonitrile/selenium disulfide (pPAN/SeS₂) composite, synthesized by heating polyacrylonitrile/polystyrene fibers with SeS₂ at 380°C under nitrogen, achieves an active material loading of 63 wt% SeS₂ and delivers a reversible capacity exceeding 1100 mAh g⁻¹ at 0.2 A g⁻¹ for lithium storage, with stability over 2000 cycles at 4.0 A g⁻¹. Similarly, for sodium storage, the same composite provides over 900 mAh g⁻¹ at 0.1 A g⁻¹, maintaining performance across 400 cycles at 1.0 A g⁻¹, attributed to the multichannel one-dimensional fiber structure that uniformly distributes Se and S atoms and bonds them to carbon backbones, mitigating volume expansion and dissolution issues. Beyond and sodium systems, SeS₂ composites have been explored in potassium-sulfur (K-S) batteries. SeS₂-based cathodes enable stable cycling, leveraging the material's thermal stability and reduced solubility of intermediate polyselenides compared to analogs. These applications highlight SeS₂'s role in advancing beyond-lithium , where its chain-like SeₓSᵧ structure provides a high volumetric capacity. SeS₂ nanoparticles have shown potential in for and exhibit antibacterial properties. SeS₂'s integration into , such as carbon composites, expands its utility by improving ion diffusion and structural integrity. These developments underscore SeS₂'s versatility in material science, driven by its chalcogenide chemistry that balances high with processability in composite forms.